About The ASCR Network
- Hits: 2511
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
- What are Adult Stem Cells?
- Why is Adult Stem Cell Research Important?
- Get Involved with ASCR Network!
Available Clinical Trials
Multiple additional trials are presently ongoing – please contact Cell Therapy Foundation for additional information or specific inquiries.
New Stem Cell Platform Technology Recognized With Patent Award
- Hits: 53
NATICK, MA--(Marketwired - Nov 26, 2013) - Stem cell therapeutics provider Parcell Laboratories announced that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 8,574,567 entitled "Multipotent Stem Cells and Uses Thereof" on November 5. The newly issued patent concerns the Early Lineage Adult (ELA®) stem cell, and relates to providing an isolated population of stem cells that exist in the synovial fluid, blood, and other tissues in the body, and related therapeutic methods. Parcell Laboratories holds the exclusive worldwide license to the ELA stem cell platform technology, which was originally discovered by scientists affiliated with the Brigham and Women's Hospital and Harvard Medical School. This multipotent stem cell patent has a term extending through 2028.
ELA cells represent the industry's newest stem cell platform technology, offering potential uses in a number of different therapeutic applications. The cells may be distinguished from other adult stem cells in several ways. First, ELA cells appear to harbor the flexibility one would normally associate with only embryonic stem cells (ESCs), offering greater potential to differentiate into a wider array of more developed cell types. In contrast to ESCs, ELA cells are not associated with higher tumor-generating potential and come without the ethical controversies attached to embryonic cells. Furthermore, ELA cells do not express the surface markers generally associated with other adult stem cells, thereby reaffirming the ELA cell population as unique. ELA cells are easily harvested from the synovial fluid of patients with osteoarthritis of the knee, but evidence suggests that they can be found throughout the body, an avenue of investigation that Parcell Laboratories is actively pursuing. Importantly, the patent allows for the culture expansion of the ELA cell into large master cell banks, which enables the company to grow the cells in tissue culture for therapeutic use, allowing for a non-controversial and scalable supply of easily attainable, highly-plastic stem cells.
Scientists create artificial skin from stem cells of umbilical cord
- Hits: 50
Published on November 25, 2013 at 4:57 AM
Spanish scientists, from the Tissue Engineering Research Group, from the Dept. of Histology at the University of Granada, have managed, for the first time, to grow artificial skin from stem cells of umbilical cord. Their study, published in the prestigious journal Stem Cells Translational Medicine, shows the ability of Wharton jelly mesenchymal stem cells to turn to oral-mucosa or skin-regeneration epithelia.
To grow the artificial skin, the researchers have used, in addition this new type of epithelia covering, a biomaterial made of fibrin and agarose, already designed and developed by the University of Granada research team. The work has been carried out in the laboratories of the Faculty of Medicine, alongside the Experimental Unit of the Granada "Virgen de las Nieves" University Hospital Complex.
Bioheart Announces New Clinical Site in Mexico
- Hits: 55
SUNRISE, FL--(Marketwired - Nov 25, 2013) - Bioheart, Inc. (OTCQB: BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
The therapy involved the use of stem cells derived from the patient's own fat (adipose tissue) obtained using liposuction. The recovered stem cells were injected into the patients' heart with Bioheart's MyoCath® needle injection catheter which allows for introduction of the cells directly into the heart without invasive surgery.
Dr. Rafael Moguel, the treating Interventional Cardiologist and head of the cardiac program at the Centro Medico de Cozumel, commented on Bioheart's therapy, "Our center is very excited to participate in the cutting edge programs at Bioheart. We can offer new hope to patients suffering from debilitating diseases by utilizing regenerative medicine and delivering these non-invasively into the heart."
Jewish Heritage Fund for Excellence gives $2 million to stem cell treatment of heart attacks
- Hits: 56
Monday, November 25, 2013
The University of Louisville announced that the Jewish Heritage Fund for Excellence is providing just over $2 million to help cardiology research Dr. Roberto Bolli move his research another step closer to being able to help potentially millions of people throughout the world.
The university also announced it was providing nearly $1 million from proceeds from a previous gift from former UofL board chair, the late Owsley Frazier, bringing the total to $3 million in support of Bolli’s groundbreaking work.
The funds will be used to purchase and install a Current Good Manufacturing Practices facility required by the Food and Drug Administration for processing the stem cells for use in the study participants.